Kshitij Anand of ET has identified five companies recommended by brokerages with the potential to become multi-baggers
Posts tagged IndiaNivesh
Ajanta Pharma Is Upgraded To Hold From Sell: IndiaNivesh
IndiaNivesh has issued an update report stating that the ‘Sell’ rating for Ajanta Pharma has been changed to ‘Hold’. Cogent reasons have been given on what has prompted the change in rating
Best Sectors & Stocks After Q2FY15 Results: IndiaNivesh
IndiaNivesh has conducted a comprehensive review of companies in various sectors and identified the best stocks that one can buy now
Amar Ambani’s Stock Pick Lumax Auto Tech Gives 50% Gain In 10 Weeks. Daljeet Kohli Sees More Upside From It
Auto ancillary & component stocks have become the red-hot favourite amongst savvy investors. All stocks of this sector are delivering bumper gains. Daljeet Kohli has homed in on two of them
Update On Stocks After Q2FY15 Results: IndiaNivesh
IndiaNivesh has provided an update on the status of the stocks in their coverage universe after the Q2FY15 results
Update On 5 Pharma Stocks After Q2FY15 Results: IndiaNivesh
IndiaNivesh has provided an update on the status of five Pharma stocks in their coverage universe after the Q2FY15 results
Is Camson Bio Tech The Next Kaveri Seeds + PI Industries?
Dharmesh Kant of IndiaNivesh has announced Camson Bio Technologies, a small cap, as his latest stock pick. Given his stellar track record in finding winning stocks, we need to keep a hawk eye on Camson
Should We Buy Or Sell Ajanta Pharma Now?
Ajanta Pharma has been a great wealth-creator stock. It reported robust Q2FY15 results. However, have the valuations run up ahead of fundamentals and should we sell the stock?
Ajay Relan’s Promise Comes True. MPS Surges 20% & Gives 286% Gain In 10M
Ajay Relan of CX Advisors deserves to be complimented for his brilliant stock picking. His stock pick, MPS, surged 20% today, giving a total return of 286% in just 10 months
Mastek Has Potential For 100%+ Gains: Daljeet Kohli
Daljeet Kohli of IndiaNivesh has issued an update report on Mastek in the wake of its Q2FY15 results. He says that the results are “above expectation” and that the stock has a target price of Rs. 550, which means a 100%+ upside from the CMP of Rs. 258
Recent Comments